X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs IPCA LABS - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA IPCA LABS GSK PHARMA/
IPCA LABS
 
P/E (TTM) x 64.3 38.4 167.5% View Chart
P/BV x 10.3 2.9 350.8% View Chart
Dividend Yield % 1.2 0.2 702.2%  

Financials

 GSK PHARMA   IPCA LABS
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
IPCA LABS
Mar-17
GSK PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3,838643 596.9%   
Low Rs2,637503 524.5%   
Sales per share (Unadj.) Rs354.2254.4 139.2%  
Earnings per share (Unadj.) Rs39.816.1 247.4%  
Cash flow per share (Unadj.) Rs42.929.8 144.0%  
Dividends per share (Unadj.) Rs30.001.00 3,000.0%  
Dividend yield (eoy) %0.90.2 530.9%  
Book value per share (Unadj.) Rs236.9194.6 121.8%  
Shares outstanding (eoy) m84.70126.20 67.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.12.3 405.9%   
Avg P/E ratio x81.435.7 228.4%  
P/CF ratio (eoy) x75.519.2 392.5%  
Price / Book Value ratio x13.72.9 464.0%  
Dividend payout %75.46.2 1,212.4%   
Avg Mkt Cap Rs m274,21672,300 379.3%   
No. of employees `0004.713.3 35.3%   
Total wages/salary Rs m4,8306,960 69.4%   
Avg. sales/employee Rs Th6,387.02,413.5 264.6%   
Avg. wages/employee Rs Th1,028.3523.2 196.6%   
Avg. net profit/employee Rs Th717.1152.4 470.4%   
INCOME DATA
Net Sales Rs m30,00032,106 93.4%  
Other income Rs m728226 322.6%   
Total revenues Rs m30,72832,332 95.0%   
Gross profit Rs m4,1904,448 94.2%  
Depreciation Rs m2631,730 15.2%   
Interest Rs m0241 0.0%   
Profit before tax Rs m4,6552,703 172.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,744675 258.3%   
Profit after tax Rs m3,3682,028 166.1%  
Gross profit margin %14.013.9 100.8%  
Effective tax rate %37.525.0 150.0%   
Net profit margin %11.26.3 177.7%  
BALANCE SHEET DATA
Current assets Rs m16,74217,340 96.6%   
Current liabilities Rs m7,2029,559 75.3%   
Net working cap to sales %31.824.2 131.2%  
Current ratio x2.31.8 128.2%  
Inventory Days Days52100 51.7%  
Debtors Days Days2157 36.5%  
Net fixed assets Rs m8,63520,779 41.6%   
Share capital Rs m847252 335.6%   
"Free" reserves Rs m19,22224,499 78.5%   
Net worth Rs m20,06924,553 81.7%   
Long term debt Rs m103,517 0.3%   
Total assets Rs m30,03839,595 75.9%  
Interest coverage xNM12.2-  
Debt to equity ratio x00.1 0.3%  
Sales to assets ratio x1.00.8 123.2%   
Return on assets %11.25.7 195.7%  
Return on equity %16.88.3 203.2%  
Return on capital %25.510.5 242.8%  
Exports to sales %048.6 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA15,617 0.0%   
Imports (cif) Rs mNA4,571 0.0%   
Fx inflow Rs m52815,617 3.4%   
Fx outflow Rs m7,1935,828 123.4%   
Net fx Rs m-6,6659,790 -68.1%   
CASH FLOW
From Operations Rs m2,3602,764 85.4%  
From Investments Rs m3,008-1,432 -210.1%  
From Financial Activity Rs m-5,108-1,591 321.0%  
Net Cashflow Rs m260-259 -100.6%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 11.4 89.5%  
FIIs % 23.8 25.3 94.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 17.4 88.5%  
Shareholders   102,036 36,892 276.6%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  NOVARTIS  J.B.CHEMICALS  SHASUN PHARMA  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Higher; ONGC Rallies 6.3%(09:30 am)

Asian stock markets traded on a mixed note in morning trade as market participants kept an eye on political developments in the U.S. after a government shutdown began last week.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jan 22, 2018 11:51 AM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS